PRESS RELEASES

Invenra and AgonOx Enter Collaboration to Discover Therapeutic Antibodies Against Novel Immuno-Oncology Target

December 13, 2016

 

 

MADISON, WI, and PORTLAND, OR, December 13, 2016 – Invenra, Inc., a pre-clinical stage bio-pharmaceutical company focused on next-generation therapeutic human antibodies, bispecifics and antibody derivatives, and AgonOx, a biotechnology company developing a pipeline of immunotherapy drugs targeting key regulators of the immune response to cancer, today announced a collaboration to identify and characterize a panel of fully human therapeutic monoclonal antibodies (mAbs) against a novel immuno-oncology target that AgonOx has identified utilizing its discovery platform. Financial details of the deal were not disclosed.

Invenra’s proprietary platform is based on ultra-high throughput technology allowing function forward screening of full-length antibodies using Invenra’s mAbSeq™ technology, where antibodies can be directly and quickly interrogated in a multi-plexed fashion with a diverse set of immunotypic and biologically relevant assays. The Invenra technology allows rapid identification of high affinity mAbs with the broadest epitope coverage possible while simultaneously performing direct phenotypic screening to isolate those mAbs with the most relevant biological activity, thus leading to the election of the best lead compounds for further development.

AgonOx’s approach to target discovery begins with genomic and proteomic analyses of tumor-
infiltrating lymphocytes isolated from human tumor biopsies. Candidates identified by these analyses are further validated using in-vitro assays and predictive in vivo murine cancer models. Andrew Weinberg, President of AgonOx, said “Collaborating with Invenra strengthens our efforts to develop immuno-oncology drug candidates through their novel antibody platform and complements our mission of discovering and delivering science that can change the standard of care for patients with cancer. Invenra has first-rate scientists that we hope to work with for years to come.”

Roland Green, CEO and president of Invenra, said, “This collaboration is a major milestone for Invenra as a company and a validation of our innovative technology. We are delighted to be collaborating with the excellent team at AgonOx to identify best-in-class antibodies against their novel immuno-oncology target. In addition, this collaboration with AgonOx fits well within our business model, whereby we are partnering with a select group of companies while continuing to develop our own internal proprietary pipeline of therapeutic product candidates.”

###

About Invenra, Inc.
Invenra is a pre-clinical stage bio-pharmaceutical company focused on discovering the next generation of best-in-class biologics, with an emphasis on monoclonal antibodies (mAbs), bispecific antibodies using their proprietary B-Body™ and TAIL™ platforms, empowered mAbs and their derivatives. Invenra’s proprietary technology combines state-of-the-art libraries and in vitro display methodologies, cell-free expression of full-length antibodies and extreme miniaturization enabling the screening of unprecedented numbers of full-length antibodies in direct phenotypic assays. For the first time, all potential antibodies of interest in a library can be screened for biological activity and other desirable traits. Invenra’s platform technology will produce the broadest epitope coverage possible and co-optimization of antibody design goals with biological activity will result in the highest caliber lead therapeutics.

About AgonOx
Agonox is a privately held, biotechnology company developing a pipeline of novel immunotherapy drugs targeting key regulators of the immune response to cancer. In 2011, in partnership with Providence Health & Services-Oregon, AgonOx entered into an exclusive global partnership with MedImmune, the global biologics arm of AstraZeneca, to develop its OX40 agonist program. Phase I clinical trials of Agonox’s OX40 agonist commenced in September of 2014.
 
SOURCE: Invenra, Inc.

Media Contacts

Dr. Roland Green
CEO and President
Invenra, Inc.
+1 (608) 441-8178
rgreen@invenra.com

Grant Risdon, Ph.D.
Head, Corporate Development
Agonox, Inc.
Grant.risdon@agonox.com

 

 

Please reload

Featured Posts

Invenra Announces Expansion of Collaboration with Exelixis

October 31, 2019

1/1
Please reload

Recent Posts
Please reload

Archive
Please reload

Invenra®

505 South Rosa Road; Suite 235, Madison, WI 53719       info@invenra.com  |   608.441.8319

connect with us
  • Twitter - Black Circle
  • LinkedIn - Black Circle

© 2018 Invenra, Inc. All Rights Reserved.